Clinical Programs for Partnering

Unlabeled Antibodies
ProgramTargetIndicationStage Territory
Epratuzumab CD22All indicationsPhase IIWorldwide
VeltuzumabCD20All indicationsPhase IIWorldwide
MilatuzumabCD74All indicationsPhase IWorldwide
IMMU-114HLA-DRAll indicationsPhase IWorldwide
Antibody-Drug Conjugates
ProgramTarget Indication Stage Territory
IMMU-132TROP-2 Solid cancersPhase II Ex-US
IMMU-130CEACAM5Colorectal cancerPhase IIWorldwide
Milatuzumab-doxorubicinCD74All indicationsPhase IWorldwide
Radiolabeled Antibodies
ProgramTargetIndicationStageTerritory
90Y-Epratuzumab tetraxetanCD22OncologyPhase IIWorldwide